Trends in reporting histological subtyping of renal cell carcinoma: association with cancer center type

被引:26
|
作者
Gansler, Ted [1 ]
Fedewa, Stacey [1 ]
Amin, Mahul B. [2 ]
Lin, Chun Chieh [1 ]
Jemal, Ahmedin [1 ]
机构
[1] Amer Canc Soc, Intramural Res, Atlanta, GA 30303 USA
[2] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA
关键词
Renal cell carcinoma; Pathology; Classification; Registries; Healthcare quality; INTERNATIONAL-SOCIETY; PRACTICES RECOMMENDATIONS; CLASSIFICATION; IMMUNOHISTOCHEMISTRY; SURVIVAL; DATABASE; SYSTEM; IMPACT; TUMORS;
D O I
10.1016/j.humpath.2018.01.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histological classification of renal cell carcinoma (RCC) has become increasingly important for clinical management. We identified 295 483 RCC diagnosed from 1998-2014 in the National Cancer Database (NCDB) to examine temporal trends in proportions of RCC with unspecified histology and several specific histologies from the 1998 and 2004 World Health Organization classifications of RCC. Further, multivariable log binomial analysis of 101 062 RCC diagnosed from 2010 to 2014 was used to determine whether the association of diagnosing/treating facility type and the proportion of unspecified RCC is independent of patient demographic and clinical factors. Between 1998 and 2014, the proportion of histologically unspecified RCC decreased substantially in all facility types, with the decrease smallest in community programs (from 86.0% to 28.1%) and largest in National Cancer Institute designated centers (from 85.1% to 9.8%). These decreases were offset by increases in percentages of papillary, clear cell, and chromophobe RCC cases. During 2010 to 2014, relative to community programs, RCCs were 21% less likely to be reported as unspecified histology (adjusted prevalence ratio [aPR] = 0.79; 95% CI, 0.68-0.92) in comprehensive community programs, 32% less likely in integrated network programs (aPR = 0.68; 95% CI, 0.57-0.92) and academic programs (aPR = 0.68; 95% CI, 0.54-0.87), and 63% less likely (aPR = 0.37; 95% CI, 0.26-0.52) in National Cancer Institute designated programs. These results have implications for the optimal selection of targeted systemic therapies for patients with advanced disease, and for the potential value of cancer registry data in pathology quality improvement programs to promote more rapid and consistent adoption of new classifications of RCC and other neoplasms. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 50 条
  • [31] A nomogram for predicting cancer-specific survival and overall survival in elderly patients with nonmetastatic renal cell carcinoma
    Zhanghuang, Chenghao
    Wang, Jinkui
    Zhang, Zhaoxia
    Yao, Zhigang
    Ji, Fengming
    Li, Li
    Xie, Yucheng
    Yang, Zhen
    Tang, Haoyu
    Zhang, Kun
    Wu, Chengchuang
    Yan, Bing
    FRONTIERS IN SURGERY, 2023, 9
  • [32] Type 2 and Clear Cell Papillary Renal Cell Carcinoma, and Tubulocystic Carcinoma: A Unifying Concept
    Brennan, Catriona
    Srigley, John R.
    Whelan, Clair
    Cooper, John
    Delahunt, Brett
    ANTICANCER RESEARCH, 2010, 30 (02) : 641 - 644
  • [33] First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience
    Rudresha, A. H.
    Chaudhuri, Tamojit
    Lakshmaiah, K. C.
    Babu, Govind K.
    Lokanatha, D.
    Jacob, Linu Abraham
    Babu, Suresh M. C.
    Lokesh, K. N.
    Rajeev, L. K.
    INDIAN JOURNAL OF CANCER, 2017, 54 (04) : 626 - 630
  • [34] Association of RASSF1A genotype and haplotype with the progression of clear cell renal cell carcinoma in Japanese patients
    Kawai, Yoshihisa
    Sakano, Shigeru
    Okayama, Naoko
    Suehiro, Yutaka
    Matsuyama, Hideyasu
    Hinoda, Yuji
    BJU INTERNATIONAL, 2012, 110 (07) : 1070 - 1075
  • [35] Trends and Outcomes in Sarcomatoid Renal Cell Carcinoma: Analysis of the National Cancer Data Base
    Wang, Luke L.
    Puri, Dhruv
    Saitta, Cesare
    Liu, Franklin
    Afari, Jonathan A.
    Meagher, Margaret F.
    Hakimi, Kevin
    Nguyen, Mimi, V
    Shah, Aastha
    Ghassemzadeh, Saeed
    Murphy, James D.
    Javier-Desloges, Juan
    Mckay, Rana R.
    Derweesh, Ithaar H.
    EUROPEAN UROLOGY OPEN SCIENCE, 2025, 71 : 96 - 105
  • [36] Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis
    Saleeb, Rola M.
    Brimo, Fadi
    Farag, Mina
    Rompre-Brodeur, Alexis
    Rotondo, Fabio
    Beharry, Vidya
    Wala, Samantha
    Plant, Pamela
    Downes, Michelle R.
    Pace, Kenneth
    Evans, Andrew
    Bjarnason, Georg
    Bartlett, John M. S.
    Yousef, George M.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (12) : 1618 - 1629
  • [37] Treatment Trends for Stage I Renal Cell Carcinoma
    Cooperberg, Matthew R.
    Mallin, Katherine
    Kane, Christopher J.
    Carroll, Peter R.
    JOURNAL OF UROLOGY, 2011, 186 (02) : 394 - 399
  • [38] Renal cell neoplasm of oncocytosis: a type of unclassified renal cell carcinoma
    Shinohara, Masatake
    Samma, Shoji
    Matsumoto, Yoshihiro
    Kagebayashi, Yoriaki
    Nakai, Yasushi
    Torimoto, Kazumasa
    Shimada, Keiji
    CEN CASE REPORTS, 2014, 3 (01): : 10 - 13
  • [39] Studying the association between breast cancer and renal cell carcinoma
    Jazieh, Khalid
    Baidoun, Firas
    Torrejon, Nataly
    Merjaneh, Zahi
    Saad, Anas
    Gad, Mohamed
    Farouk, Amal
    Ornstein, Moshe
    Abraham, Jame
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 191 (03) : 643 - 652
  • [40] Multi-sequence MRI-based radiomics model to preoperatively predict the WHO/ISUP grade of clear Cell Renal Cell Carcinoma: a two-center study
    Chen, Ruihong
    Su, Qiaona
    Li, Yangyang
    Shen, Pengxin
    Zhang, Jianxin
    Tan, Yan
    BMC CANCER, 2024, 24 (01)